Neuroprotective effects of Ibudilast, a Phosphodiesterase IV inhibitor in mouse model of Parkinson’s disease
Objective: In the present study, we examined neuroprotective effects, if any, of IBD drug, a inhibitor of the phosphodiesterase IV in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse…Medication safety in Parkinson’s disease patients: evaluation of recommendations for decision support in the national drug-disease interaction database
Objective: Objective: Drug-disease interactions in Parkinson's disease patients can give rise to situations where a drug may have negative effects on both motor- and non-motor…Covid vaccine induced parkinsonism and cognitive dysfunction
Objective: To describe movement disorder and cognitive impairment in two patients following COVID-19 vaccination. Background: The manifestation of neurological complications have been increasingly evidenced following…Beta-agonists and risk of Parkinson’s disease: Meta-analysis of real-world evidence studies
Objective: We performed a systematic review and meta-analysis of real-world evidence (RWE) studies evaluating the association between use of beta-agonist and the risk of PD.…Belly Dance Dyskinesia, a manifestation of B12 deficiency and hyperhomocysteinuria in MTHFR gene mutation. Videographic record of a case.
Objective: We present a case of probable Belly Dance Dyskinesia (BDD) secondary to vitamin B12 deficiency. Background: BDD is a rare movement disorder (considered a…To be or not to bupropion: a drug-induced parkinsonism?
Objective: To draw attention to drug-induced parkinsonism. Background: Although the main causes of parkinsonism are degenerative, there are some reversible causes, including drug-induced parkinsonism. Method:…Levosulpiride and Movement Disorders–A Growing Concern
Objective: To describe a series of patients with levosulpiride (LVS) induced movement disorders (LIM) evaluated at a single movement disorder center, the All India Institute…A STUDY OF CLINICAL SPECTRUM, RISK FACTORS AND OUTCOME OF DRUG-INDUCED MOVEMENT DISORDERS
Objective: We aimed to characterize the spectrum of DIMDs, and the culprit agents commonly encountered in the movement disorder clinic. We also set out to…Carboplatin, Paclitaxel, and Nivolumab-induced Parkinsonism Responsive to Levodopa
Objective: To present the first reported case of reversible, levodopa sensitive, chemotherapy- induced parkinsonism due to the combination of carboplatin, paclitaxel, and nivolumab. Background: Many case reports describe antineoplastic agents causing reversible parkinsonism, most commonly, cyclophosphamide, cytosine arabinoside, and cyclosporine. To our knowledge, drug-induced parkinsonism related to combination therapy of paclitaxel, carboplatin, and nivolumab has never been…Beta-antagonists and risk of Parkinson’s disease: Meta-analysis of real-world evidence studies
Objective: We performed a systematic review and meta-analysis of real-world evidence (RWE) studies evaluating the association between use of β-antagonist and the risk of PD.…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 10
- Next Page »